A share price of BioAge Labs Inc [BIOA] is currently trading at $12.75, up 0.55%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BIOA shares have gain 21.43% over the last week, with a monthly amount glided 62.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioAge Labs Inc [NASDAQ: BIOA] stock has seen the most recent analyst activity on December 05, 2025, when Morgan Stanley upgraded its rating to a Equal-Weight but kept the price target unchanged to $12 for it. Previously, Citigroup upgraded its rating to Buy on October 22, 2025, and kept the price target unchanged to $10. On February 28, 2025, William Blair initiated with a Mkt Perform rating. Morgan Stanley downgraded its rating to a Underweight and decreased its price target to $5 on December 10, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $7 on December 09, 2024. Citigroup downgraded its rating to Neutral for this stock on December 09, 2024, and downed its price target to $7. In a note dated October 21, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
BioAge Labs Inc experienced fluctuations in its stock price throughout the past year between $2.88 and $12.80. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. BioAge Labs Inc [NASDAQ: BIOA] shares were valued at $12.75 at the most recent close of the market. An investor can expect a potential drop of -5.88% based on the average BIOA price forecast.
Analyzing the BIOA fundamentals
Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -15.16%, Pretax Profit Margin comes in at -12.81%, and Net Profit Margin reading is -12.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.25 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.13 points at the first support level, and at 11.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.23, and for the 2nd resistance point, it is at 13.72.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioAge Labs Inc [NASDAQ:BIOA] is 11.87. In addition, the Quick Ratio stands at 11.87 and the Cash Ratio stands at 8.8. Considering the valuation of this stock, the price to sales ratio is 77.22, the price to book ratio is 1.65.
Transactions by insiders
Recent insider trading involved RUBIN PAUL D, Chief Medical Officer, that happened on Dec 09 ’25 when 18000.0 shares were sold. Officer, RUBIN PAUL D completed a deal on Dec 09 ’25 to buy 18000.0 shares. Meanwhile, Chief Medical Officer RUBIN PAUL D sold 68897.0 shares on Dec 04 ’25.
